Apixaban
- Generic Name
- Apixaban
- Brand Names
- Eliquis, Apixaban Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N5O4
- CAS Number
- 503612-47-3
- Unique Ingredient Identifier
- 3Z9Y7UWC1J
- Background
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.
- Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
- Associated Therapies
- -
Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in Cancer Patients
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Michael Kovacs
- Target Recruit Count
- 70
- Registration Number
- NCT03100071
- Locations
- 🇨🇦
London Health Science Center, Victoria Hospital, London, Ontario, Canada
🇨🇦Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus
- Conditions
- Interventions
- First Posted Date
- 2017-03-20
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 12
- Registration Number
- NCT03083782
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-03-15
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 370
- Registration Number
- NCT03080883
- Locations
- 🇺🇸
Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States
🇺🇸Carle Cancer Center, Urbana, Illinois, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer
- First Posted Date
- 2017-02-07
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Fadoi Foundation, Italy
- Target Recruit Count
- 1168
- Registration Number
- NCT03045406
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
🇺🇸Mayo Clinic Jacksonville, Jacksonville, Florida, United States
A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
- Conditions
- Interventions
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 192
- Registration Number
- NCT02981472
- Locations
- 🇮🇹
Local Institution - 0026, Rome, Roma, Italy
🇺🇸Children'S Hospital Colorado, Aurora, Colorado, United States
🇺🇸Local Institution - 0013, Ann Arbor, Michigan, United States
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Gregory Piazza
- Target Recruit Count
- 50
- Registration Number
- NCT02958969
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2016-11-01
- Target Recruit Count
- 100
- Registration Number
- NCT02946944
- Locations
- 🇷🇺
Federal State Institution Academician E.N.Meshalkin Novosibirsk State Research Institute Of Circulation Pathology Rusmedtechnology, Novosibirsk, Russian Federation
Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis
- Conditions
- Interventions
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Intermountain Health Care, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT02945280
- Locations
- 🇺🇸
Intermountain Medical Center, Murray, Utah, United States
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Christopher Granger, MD
- Target Recruit Count
- 154
- Registration Number
- NCT02942407
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Nephrology & Hypertension Associates, Tupelo, Mississippi, United States
🇺🇸Nuren Medical and Research Center, Miami, Florida, United States
ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)
- Conditions
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- University of Pavia
- Target Recruit Count
- 300
- Registration Number
- NCT02935855
- Locations
- 🇮🇹
IRCCS Policlinico San Matteo, Pavia, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.